Impact of Target Lesion Revascularization on Long-Term Mortality After Percutaneous Coronary Intervention for Left Main Disease.
Tae Oh Kim, Do-Yoon Kang, Jung-Min Ahn...
https://pubmed.ncbi.nlm.nih.gov/38199751/Actively Recruiting
Led by Seung-Jung Park · Updated on 2026-10-15
10000
Participants Needed
42
Research Sites
52 weeks
Total Duration
Researchers are observing the long-term clinical outcomes for patients with unprotected left main coronary artery LMCA disease. The study aims to compare results of different treatments including medical therapy, coronary stenting with drug-eluting stents, and coronary artery bypass grafting CABG in routine clinical practice. This large, multicenter registry collects real-world data from about 5000 patients diagnosed with significant LMCA stenosis across multiple centers in the Asia-Pacific region. Participants diagnosed with unprotected LMCA stenosis of more than 50% blockage will be followed as they receive various treatments determined by their doctors, including medications, PCI with drug-eluting stents, or CABG. The study does not assign treatments but records outcomes as patients receive these therapies in standard care. Data collection occurs prospectively in this observational registry to reflect real-world treatment patterns. Throughout the study, participants will be monitored for up to 10 years to track important outcomes such as death, cardiac death, myocardial infarction, cerebrovascular events, and the need for repeat interventions. Additional assessments include rehospitalization and stent-related complications. Data is collected through clinical follow-ups as per the study schedule. This long-term observation aims to understand the comparative effectiveness and safety of treatments for unprotected LMCA disease in everyday medical practice.
CONDITIONS
Observational Study for Left Main Disease Treatment
S
Seung-Jung Park, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Seung-Jung Park
Lead Sponsor
CardioVascular Research Foundation, Korea
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants are followed over time during their usual treatment to collect clinical data and track health outcomes.
Regular clinical follow-up visits as scheduled
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Tae Oh Kim, Do-Yoon Kang, Jung-Min Ahn...
https://pubmed.ncbi.nlm.nih.gov/38199751/Se Hun Kang, Jung-Min Ahn, Cheol Hyun Lee...
https://pubmed.ncbi.nlm.nih.gov/28701487/Sangwoo Park, Jung-Min Ahn, Hanbit Park...
https://pubmed.ncbi.nlm.nih.gov/34233836/Sungsoo Cho, Do-Yoon Kang, Jung-Sun Kim...
https://pubmed.ncbi.nlm.nih.gov/35907438/Sangwoo Park, Jung-Min Ahn, Tae Oh Kim...
https://pubmed.ncbi.nlm.nih.gov/32943156/Seung-Jung Park
Lead Sponsor
CardioVascular Research Foundation, Korea
Collaborating Sponsor